Tocilizumab biosimilar - Bio-Thera Solutions

Drug Profile

Tocilizumab biosimilar - Bio-Thera Solutions

Alternative Names: BAT 1806

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bio-Thera Solutions
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Juvenile rheumatoid arthritis

Most Recent Events

  • 26 Jul 2018 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (IV)
  • 04 Apr 2018 Preclinical trials in Juvenile rheumatoid arthritis in China (IV, Infusion) before April 2018 (Bio-Thera Solutions Pipeline, April 2018)
  • 04 Apr 2018 Preclinical trials in Rheumatoid arthritis in China (IV, Infusion) before April 2018 (Bio-Thera Solutions Pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top